The TSC Preclinical Consortium invites researchers and industry partners to request testing of new compounds.
The TSC Preclinical Consortium engages academic researchers and pharmaceutical industry researchers in a collaborative effort to accelerate new compounds into the late stages of preclinical development.
Over the past several months, the Consortium has established video-EEG analysis at PsychoGenics, Inc., of Tsc1flox/flox;GFAP-Cre+ mice obtained from Dr. Michael Wong’s lab at Washington University in St. Louis. Dr. Wong has been instrumental in helping the TSC Alliance and PsychoGenics establish experimental protocols and analysis of results. Four compounds have been tested to-date, and a fifth is underway. Additionally, analysis of results from a biomarker study in this model is in progress.
A Steering Committee sets the long-term goals and priorities. Working Groups choose the best disease-relevant models and assays and provide oversight for rigorous quality control and interpretation of results. Three industry partners and two academic research institutions have joined the consortium.
The TSC Alliance supports testing of compounds for which data can be shared freely among all consortium members. Researchers and industry partners may request testing of specific compounds or suggest relevant mechanisms of interest. The TSC Preclinical Consortium can also facilitate the testing of proprietary compounds from industry partners. By paying the full cost of testing those molecules, a company can retain sole ownership of data.
For more information, contact Steve Roberds or Dani Brunner. The TSC Preclinical Consortium is coordinated and wholly funded by the TSC Alliance thanks to generous support from the Cowlin Family Fund, The Engles Collaborative Research Fund, industry partners, and many additional donors through the Unlock the Cure campaign.